Rojanaporn Duangnate, Attaseth Taweevat, Dieosuthichat Wimwipa, Leelawongs Kitikul, Pakakasama Samart, Anurathapan Usanarat, Chanthanaphak Ekachat, Singhara Na Ayudhaya Sirintara, Aroonroch Rangsima, Hongeng Suradej
Department of Ophthalmology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.
Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.
J Ophthalmol. 2020 Sep 10;2020:4231841. doi: 10.1155/2020/4231841. eCollection 2020.
To investigate the clinical presentations and outcomes of retinoblastoma in relation to the advent of new multimodal treatments in Thailand. Retrospective case series. We evaluated the clinical presentation, staging, details of treatment, and treatment outcomes of retinoblastoma patients who were treated at Ramathibodi Hospital, Bangkok, Thailand, between January 1, 2007, and December 31, 2018. The log-rank test was used to explore clinical characteristics and treatment modalities that affected globe salvage and survival curves.
This study included 124 eyes of 81 patients with retinoblastoma. Forty-three patients (53.1%) had bilateral retinoblastoma. The median age at diagnosis was 8 months (range, 1-48 months). Of 124 eyes, 9 eyes (7.3%) had extraocular retinoblastoma and 115 eyes (92.7%) had intraocular retinoblastoma, which were classified by the International Classification of Retinoblastoma (ICRB) as group A, 4 eyes (3.5%); group B, 19 eyes (16.5%); group C, 6 eyes (5.2%); group D, 31 eyes (27%); and group E, 56 eyes (47.8%). Treatment included systemic chemotherapy, intra-arterial chemotherapy, ruthenium-106 plaque brachytherapy, external beam radiation therapy, cryotherapy, transpupillary thermotherapy, subtenon chemotherapy, and intravitreal chemotherapy. At the median follow-up period of 38.4 months (range, 0.2-148.2 months), the overall globe salvage rate of intraocular retinoblastoma was 51.7%. For unilateral retinoblastoma, globe salvage rate was 37.5% (group B, 100%; group C, 100%; group D, 50%; and group E, 18.8%). For bilateral intraocular retinoblastoma, the globe salvage rate was 57.8% (group A, 100 %; group B, 94.4%; group C, 100%; group D, 64.7%; and group E, 28.2%). The overall survival rate was 93.8%.
Recent advanced treatment modalities have improved the probability of globe salvage. However, enucleation remains an important life-saving intervention in many advanced cases.
探讨泰国新的多模式治疗方法出现后视网膜母细胞瘤的临床表现及治疗结果。回顾性病例系列研究。我们评估了2007年1月1日至2018年12月31日期间在泰国曼谷拉玛蒂博迪医院接受治疗的视网膜母细胞瘤患者的临床表现、分期、治疗细节及治疗结果。采用对数秩检验来探究影响眼球挽救率和生存曲线的临床特征及治疗方式。
本研究纳入了81例视网膜母细胞瘤患者的124只眼。43例患者(53.1%)患有双侧视网膜母细胞瘤。诊断时的中位年龄为8个月(范围1 - 48个月)。124只眼中,9只眼(7.3%)为眼外视网膜母细胞瘤,115只眼(92.7%)为眼内视网膜母细胞瘤,根据国际视网膜母细胞瘤分类(ICRB)分为A组4只眼(3.5%);B组19只眼(16.5%);C组6只眼(5.2%);D组31只眼(27%);E组56只眼(47.8%)。治疗方法包括全身化疗、动脉内化疗、钌 - 106敷贴近距离放疗、外照射放疗、冷冻疗法、经瞳孔温热疗法、球后化疗及玻璃体腔内化疗。在中位随访期38.4个月(范围0.2 - 148.2个月)时,眼内视网膜母细胞瘤的总体眼球挽救率为51.7%。对于单侧视网膜母细胞瘤,眼球挽救率为37.5%(B组100%;C组100%;D组50%;E组18.8%)。对于双侧眼内视网膜母细胞瘤,眼球挽救率为57.8%(A组100%;B组94.4%;C组100%;D组64.7%;E组28.2%)。总生存率为93.8%。
近期先进的治疗方式提高了眼球挽救的概率。然而,在许多晚期病例中,眼球摘除术仍是一项重要的挽救生命的干预措施。